Download PDF
Semin Liver Dis 2024; 44(03): 319-332
DOI: 10.1055/a-2338-9261
Review Article

Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets

Shengying Qian‡   *
1   Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China
2   University of Chinese Academy of Sciences, Beijing, China
,
Xiaolin Wang‡   *
3   Department of Infectious Diseases, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, China
,
Yingfen Chen
1   Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China
2   University of Chinese Academy of Sciences, Beijing, China
,
Qiuhong Zai
1   Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China
2   University of Chinese Academy of Sciences, Beijing, China
,
Yong He
1   Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China
2   University of Chinese Academy of Sciences, Beijing, China
› Author Affiliations
› Further Information
    Permissions and Reprints


Abstract

Alcohol-related liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), two main types of steatotic liver disease (SLDs), are characterized by a wide spectrum of several different liver disorders, including simple steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma. Multiple immune cell-mediated inflammatory responses not only orchestrate the killing and removal of infected/damaged cells but also exacerbate the development of SLDs when excessive or persistent inflammation occurs. In recent years, single-cell and spatial transcriptome analyses have revealed the heterogeneity of liver-infiltrated immune cells in ALD and MASLD, revealing a new immunopathological picture of SLDs. In this review, we will emphasize the roles of several key immune cells in the pathogenesis of ALD and MASLD and discuss inflammation-based approaches for effective SLD intervention. In conclusion, the study of immunological mechanisms, especially highly specific immune cell population functions, may provide novel therapeutic opportunities for this life-threatening disease.

Keywords

ALD - MASLD - macrophages - neutrophils - single-cell RNA sequencing

Author Contributions

S.Q. wrote inflammation in ALD and therapeutic targets; X.W. wrote inflammation in MASLD; Y.C. prepared [Fig. 1] and [Table 1]; Q.Z. prepared [Fig. 2]; Y.H. initiated and supervised the writing of the entire paper and edited the paper.


* S.Q. and X.W. contributed equally to this work.




Publication History

Accepted Manuscript online:
05 June 2024

Article published online:
25 June 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Eslam M, Newsome PN, Sarin SK. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73 (01) 202-209
    CrossrefPubMedGoogle Scholar
  • 2 Peacock A, Leung J, Larney S. et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 2018; 113 (10) 1905-1926
    CrossrefPubMedGoogle Scholar
  • 3 Collaborators GBDA. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018; 392 (10152): 1015-1035
    CrossrefPubMedGoogle Scholar
  • 4 Quek J, Chan KE, Wong ZY. et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023; 8 (01) 20-30
    CrossrefPubMedGoogle Scholar
  • 5 Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 2023; 7 (10) 7
    CrossrefPubMedGoogle Scholar
  • 6 Shim YR, Jeong WI. Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease. Exp Mol Med 2020; 52 (05) 772-780
    CrossrefPubMedGoogle Scholar
  • 7 Wang M, Ma LJ, Yang Y, Xiao Z, Wan JB. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: a critical review. Crit Rev Food Sci Nutr 2019; 59 (sup1): S116-S129
    CrossrefPubMedGoogle Scholar
  • 8 Wang H, Zhou H, Zhang Q. et al. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice. J Hepatol 2020; 73 (06) 1470-1481
    CrossrefPubMedGoogle Scholar
  • 9 Xu MJ, Zhou Z, Parker R, Gao B. Targeting inflammation for the treatment of alcoholic liver disease. Pharmacol Ther 2017; 180: 77-89
    CrossrefPubMedGoogle Scholar
  • 10 Rodriguez Y, Dunfield J, Roderique T, Ni HM. Liver-adipose tissue crosstalk in alcohol-associated liver disease: the role of mTOR. Liver Res 2022; 6 (04) 227-237
    CrossrefPubMedGoogle Scholar
  • 11 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24 (07) 908-922
    CrossrefPubMedGoogle Scholar
  • 12 Mehal W. Mechanisms of liver fibrosis in metabolic syndrome. eGastroenterology 2023; 1 (01) e100015
    CrossrefPubMedGoogle Scholar
  • 13 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2022; 22 (07) 429-443
    CrossrefPubMedGoogle Scholar
  • 14 Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 2018; 67 (05) 963-972
    CrossrefPubMedGoogle Scholar
  • 15 Ray K. Resmetirom proves positive for NASH with liver fibrosis. Nat Rev Gastroenterol Hepatol 2024; 21 (04) 218
    CrossrefPubMedGoogle Scholar
  • 16 Wu XQ, Yang Y, Li WX. et al. Telomerase reverse transcriptase acts in a feedback loop with NF-κB pathway to regulate macrophage polarization in alcoholic liver disease. Sci Rep 2016; 6: 18685
    CrossrefPubMedGoogle Scholar
  • 17 Kisseleva T, Brenner DA. The crosstalk between hepatocytes, hepatic macrophages, and hepatic stellate cells facilitates alcoholic liver disease. Cell Metab 2019; 30 (05) 850-852
    CrossrefPubMedGoogle Scholar
  • 18 Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015; 12 (07) 387-400
    CrossrefPubMedGoogle Scholar
  • 19 Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol 2020; 26 (02) 109-133
    CrossrefPubMedGoogle Scholar
  • 20 Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 2016; 16 (07) 407-420
    CrossrefPubMedGoogle Scholar
  • 21 de Carvalho Ribeiro M, Szabo G. Role of the inflammasome in liver disease. Annu Rev Pathol 2022; 17: 345-365
    CrossrefPubMedGoogle Scholar
  • 22 Wu X, Fan X, McMullen MR. et al. Macrophage-derived MLKL in alcohol-associated liver disease: regulation of phagocytosis. Hepatology 2023; 77 (03) 902-919
    CrossrefPubMedGoogle Scholar
  • 23 Duan Y, Chu H, Brandl K. et al. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun 2021; 12 (01) 7172
    CrossrefPubMedGoogle Scholar
  • 24 Ma HY, Yamamoto G, Xu J. et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol 2020; 72 (05) 946-959
    CrossrefPubMedGoogle Scholar
  • 25 Lee JH, Shim YR, Seo W. et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through Toll-like receptor 3 in alcohol-associated liver injury. Hepatology 2020; 72 (02) 609-625
    CrossrefPubMedGoogle Scholar
  • 26 Kim HH, Shim YR, Choi SE. et al. Catecholamine induces Kupffer cell apoptosis via growth differentiation factor 15 in alcohol-associated liver disease. Exp Mol Med 2023; 55 (01) 158-170
    CrossrefPubMedGoogle Scholar
  • 27 Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical monocytes in health and disease. Annu Rev Immunol 2019; 37: 439-456
    CrossrefPubMedGoogle Scholar
  • 28 Kim A, Bellar A, McMullen MR, Li X, Nagy LE. Functionally diverse inflammatory responses in peripheral and liver monocytes in alcohol-associated hepatitis. Hepatol Commun 2020; 4 (10) 1459-1476
    CrossrefPubMedGoogle Scholar
  • 29 Sanz-Garcia C, Poulsen KL, Bellos D. et al. The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute-on-chronic ethanol administration in mice. J Hepatol 2019; 70 (05) 974-984
    CrossrefPubMedGoogle Scholar
  • 30 Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010; 33 (05) 657-670
    CrossrefPubMedGoogle Scholar
  • 31 Khan RS, Lalor PF, Thursz M, Newsome PN. The role of neutrophils in alcohol-related hepatitis. J Hepatol 2023; 79 (04) 1037-1048
    CrossrefPubMedGoogle Scholar
  • 32 Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types?. Front Physiol 2018; 9: 113
    CrossrefPubMedGoogle Scholar
  • 33 Németh T, Sperandio M, Mócsai A. Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov 2020; 19 (04) 253-275
    CrossrefPubMedGoogle Scholar
  • 34 Li N, Liu H, Xue Y. et al. Targetable Brg1-CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking. EMBO Mol Med 2023; 15 (03) e16592
    CrossrefPubMedGoogle Scholar
  • 35 Kusumanchi P, Liang T, Zhang T. et al. Stress-responsive gene FK506-binding protein 51 mediates alcohol-induced liver injury through the hippo pathway and chemokine (C-X-C motif) ligand 1 signaling. Hepatology 2021; 74 (03) 1234-1250
    CrossrefPubMedGoogle Scholar
  • 36 Cho Y, Bukong TN, Tornai D. et al. Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis. J Hepatol 2023; 78 (01) 28-44
    CrossrefPubMedGoogle Scholar
  • 37 Ren R, He Y, Ding D. et al. Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPα-miRNA-223 axis. Hepatology 2022; 75 (03) 646-660
    CrossrefPubMedGoogle Scholar
  • 38 Ma J, Guillot A, Yang Z. et al. Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure. J Clin Invest 2022; 132 (14) 132
    CrossrefPubMedGoogle Scholar
  • 39 Artru F, Bou Saleh M, Maggiotto F. et al. IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. J Hepatol 2020; 72 (06) 1052-1061
    CrossrefPubMedGoogle Scholar
  • 40 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021; 18 (01) 73-91
    CrossrefPubMedGoogle Scholar
  • 41 He Y, Hwang S, Ahmed YA. et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol 2021; 18 (01) 18-37
    CrossrefPubMedGoogle Scholar
  • 42 Chu S, Sun R, Gu X. et al. Inhibition of sphingosine-1-phosphate-induced Th17 cells ameliorates alcohol-associated steatohepatitis in mice. Hepatology 2021; 73 (03) 952-967
    CrossrefPubMedGoogle Scholar
  • 43 Zeng S, Rosati E, Saggau C. et al. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 2023; 31 (03) 389-404.e7
    CrossrefPubMedGoogle Scholar
  • 44 Eom JA, Jeong JJ, Han SH. et al. Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease. Gut Microbes 2023; 15 (02) 2281014
    CrossrefPubMedGoogle Scholar
  • 45 Lee KC, Chen P, Maricic I. et al. Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2019; 316 (05) G585-G597
    CrossrefPubMedGoogle Scholar
  • 46 Byun JS, Yi HS. Hepatic immune microenvironment in alcoholic and nonalcoholic liver disease. BioMed Res Int 2017; 2017: 6862439
    PubMedGoogle Scholar
  • 47 Gao H, Jin Z, Bandyopadhyay G. et al. MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH. Cell Metab 2022; 34 (07) 978-990.e4
    CrossrefPubMedGoogle Scholar
  • 48 Tran S, Baba I, Poupel L. et al. Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis. Immunity 2020; 53 (03) 627-640.e5
    CrossrefPubMedGoogle Scholar
  • 49 Seidman JS, Troutman TD, Sakai M. et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. Immunity 2020; 52 (06) 1057-1074.e7
    CrossrefPubMedGoogle Scholar
  • 50 Remmerie A, Martens L, Thoné T. et al. Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver. Immunity 2020; 53 (03) 641-657.e14
    CrossrefPubMedGoogle Scholar
  • 51 Han H, Ge X, Komakula SSB. et al. Macrophage-derived osteopontin (SPP1) protects from nonalcoholic steatohepatitis. Gastroenterology 2023; 165 (01) 201-217
    CrossrefPubMedGoogle Scholar
  • 52 Xiong X, Kuang H, Ansari S. et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell 2019; 75 (03) 644-660.e5
    CrossrefPubMedGoogle Scholar
  • 53 Hendrikx T, Porsch F, Kiss MG. et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. J Hepatol 2022; 77 (05) 1373-1385
    CrossrefPubMedGoogle Scholar
  • 54 Liu L, Zhou Y, Liu Z. et al. Osr1 regulates macrophage-mediated liver inflammation in nonalcoholic fatty liver disease progression. Cell Mol Gastroenterol Hepatol 2023; 15 (05) 1117-1133
    CrossrefPubMedGoogle Scholar
  • 55 Xu F, Guo M, Huang W. et al. Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH. Redox Biol 2020; 36: 101634
    CrossrefPubMedGoogle Scholar
  • 56 Lee S, Usman TO, Yamauchi J. et al. Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis. J Clin Invest 2022; 132 (14) 132
    CrossrefPubMedGoogle Scholar
  • 57 Wang Q, Zhou H, Bu Q. et al. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. J Hepatol 2022; 77 (02) 312-325
    CrossrefPubMedGoogle Scholar
  • 58 Govaere O, Petersen SK, Martinez-Lopez N. et al. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. J Hepatol 2022; 76 (05) 1001-1012
    CrossrefPubMedGoogle Scholar
  • 59 Morikawa R, Nakamoto N, Amiya T. et al. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. J Hepatol 2021; 74 (03) 511-521
    CrossrefPubMedGoogle Scholar
  • 60 Cai B, Dongiovanni P, Corey KE. et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metab 2020; 31 (02) 406-421.e7
    CrossrefPubMedGoogle Scholar
  • 61 Qing J, Ren Y, Zhang Y. et al. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis. J Hepatol 2022; 76 (02) 394-406
    CrossrefPubMedGoogle Scholar
  • 62 Hwang S, He Y, Xiang X. et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 2020; 72 (02) 412-429
    CrossrefPubMedGoogle Scholar
  • 63 van der Windt DJ, Sud V, Zhang H. et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology 2018; 68 (04) 1347-1360
    CrossrefPubMedGoogle Scholar
  • 64 Wang X, He Y, Mackowiak B, Gao B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut 2021; 70 (04) 784-795
    CrossrefPubMedGoogle Scholar
  • 65 Hwang S, Wang X, Rodrigues RM. et al. Protective and detrimental roles of p38α mitogen-activated protein kinase in different stages of nonalcoholic fatty liver disease. Hepatology 2020; 72 (03) 873-891
    CrossrefPubMedGoogle Scholar
  • 66 Wang H, Zhang H, Wang Y. et al. Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. J Hepatol 2021; 75 (06) 1271-1283
    CrossrefPubMedGoogle Scholar
  • 67 He Y, Rodrigues RM, Wang X. et al. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J Clin Invest 2021; 131 (03) 131
    CrossrefPubMedGoogle Scholar
  • 68 Hou X, Yin S, Ren R. et al. Myeloid-cell-specific IL-6 signaling promotes MicroRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis. Hepatology 2021; 74 (01) 116-132
    CrossrefPubMedGoogle Scholar
  • 69 He Y, Hwang S, Cai Y. et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology 2019; 70 (04) 1150-1167
    CrossrefPubMedGoogle Scholar
  • 70 Calvente CJ, Tameda M, Johnson CD. et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest 2019; 129 (10) 4091-4109
    CrossrefPubMedGoogle Scholar
  • 71 Karl M, Hasselwander S, Zhou Y. et al. Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease. Hepatology 2022; 76 (04) 1135-1149
    CrossrefPubMedGoogle Scholar
  • 72 Barrow F, Khan S, Fredrickson G. et al. Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling. Hepatology 2021; 74 (02) 704-722
    CrossrefPubMedGoogle Scholar
  • 73 Kotsiliti E, Leone V, Schuehle S. et al. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J Hepatol 2023; 79 (02) 296-313
    CrossrefPubMedGoogle Scholar
  • 74 Haas JT, Vonghia L, Mogilenko DA. et al. Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. Nat Metab 2019; 1 (06) 604-614
    CrossrefPubMedGoogle Scholar
  • 75 Pfister D, Núñez NG, Pinyol R. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021; 592 (7854) 450-456
    CrossrefPubMedGoogle Scholar
  • 76 Dudek M, Pfister D, Donakonda S. et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature 2021; 592 (7854) 444-449
    CrossrefPubMedGoogle Scholar
  • 77 Moreno-Fernandez ME, Giles DA, Oates JR. et al. PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease. Cell Metab 2021; 33 (06) 1187-1204.e9
    CrossrefPubMedGoogle Scholar
  • 78 Torres-Hernandez A, Wang W, Nikiforov Y. et al. γδ T cells promote steatohepatitis by orchestrating innate and adaptive immune programming. Hepatology 2020; 71 (02) 477-494
    CrossrefPubMedGoogle Scholar
  • 79 Marinović S, Lenartić M, Mladenić K. et al. NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis. Sci Immunol 2023; 8 (87) eadd1599
    CrossrefPubMedGoogle Scholar
  • 80 Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol 2018; 113 (02) 175-194
    CrossrefPubMedGoogle Scholar
  • 81 Dasarathy S, Mitchell MC, Barton B. et al. Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis. Contemp Clin Trials 2020; 96: 106094
    CrossrefPubMedGoogle Scholar
  • 82 Verbeke L, Farre R, Trebicka J. et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59 (06) 2286-2298
    CrossrefPubMedGoogle Scholar
  • 83 Ambade A, Lowe P, Kodys K. et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology 2019; 69 (03) 1105-1121
    CrossrefPubMedGoogle Scholar
  • 84 Maccioni L, Fu Y, Horsmans Y. et al. Alcohol-associated bowel disease: new insights into pathogenesis. eGastroenterology 2023; 1 (01) e100013
    CrossrefPubMedGoogle Scholar
  • 85 Singal AK, Shah VH. Current trials and novel therapeutic targets for alcoholic hepatitis. J Hepatol 2019; 70 (02) 305-313
    CrossrefPubMedGoogle Scholar
  • 86 Philips CA, Pande A, Shasthry SM. et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol 2017; 15 (04) 600-602
    CrossrefPubMedGoogle Scholar
  • 87 Cusi K, Isaacs S, Barb D. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28 (05) 528-562
    CrossrefPubMedGoogle Scholar
  • 88 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep Innov Hepatol 2019; 1 (04) 312-328
    CrossrefPubMedGoogle Scholar
  • 89 Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014; 20 (04) 573-591
    CrossrefPubMedGoogle Scholar
  • 90 Lim LL, Chow E, Chan JCN. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nat Rev Endocrinol 2023; 19 (03) 151-163
    CrossrefPubMedGoogle Scholar
  • 91 Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 2019; 70 (02) 711-724
    CrossrefPubMedGoogle Scholar
  • 92 Cariou B. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: implications for treatment. Diabetes Obes Metab 2022; 24 (Suppl. 02) 15-27
    CrossrefPubMedGoogle Scholar
  • 93 Kahl S, Gancheva S, Straßburger K. et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 2020; 43 (02) 298-305
    CrossrefPubMedGoogle Scholar
  • 94 Latva-Rasku A, Honka MJ, Kullberg J. et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care 2019; 42 (05) 931-937
    CrossrefPubMedGoogle Scholar
  • 95 Cusi K, Bril F, Barb D. et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab 2019; 21 (04) 812-821
    CrossrefPubMedGoogle Scholar
  • 96 Benedé-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD). Gut Microbes 2024; 16 (01) 2331460
    CrossrefPubMedGoogle Scholar
  • 97 Quesada-Vázquez S, Aragonès G, Del Bas JM, Escoté X. Diet, gut microbiota and non-alcoholic fatty liver disease: three parts of the same axis. Cells 2020; 9 (01) 9
    CrossrefPubMedGoogle Scholar
  • 98 Roth JD, Feigh M, Veidal SS. et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018; 24 (02) 195-210
    CrossrefPubMedGoogle Scholar
  • 99 Ding L, Yang Q, Zhang E. et al. Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice. Acta Pharm Sin B 2021; 11 (06) 1541-1554
    CrossrefPubMedGoogle Scholar
  • 100 Kruger AJ, Fuchs BC, Masia R. et al. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun 2018; 2 (05) 529-545
    CrossrefPubMedGoogle Scholar
  • 101 Anstee QM, Neuschwander-Tetri BA, Wong VW. et al. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp Clin Trials 2020; 89: 105922
    CrossrefPubMedGoogle Scholar
  • 102 Podszun MC, Alawad AS, Lingala S. et al. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biol 2020; 37: 101710
    CrossrefPubMedGoogle Scholar
  • 103 Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. Nat Metab 2021; 3 (10) 1302-1312
    CrossrefPubMedGoogle Scholar
  • 104 Burger K, Jung F, Baumann A. et al. TNFα is a key trigger of inflammation in diet-induced non-obese MASLD in mice. Redox Biol 2023; 66: 102870
    CrossrefPubMedGoogle Scholar
  • 105 Guan Y, Peiffer B, Feng D. et al. IL-8+ neutrophils drive inexorable inflammation in severe alcohol-associated hepatitis. J Clin Invest 2024; 134 (09) 134
    CrossrefPubMedGoogle Scholar
  • 106 Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Invest 2024; 134 (03) 134
    CrossrefPubMedGoogle Scholar
  • 107 Lazarus JV, Ivancovsky Wajcman D, Mark HE. et al. Opportunities and challenges following approval of resmetirom for MASH liver disease. Nat Med 2024; (e-pub ahead of print) DOI: 10.1038/s41591-024-02958-z.
    CrossrefPubMedGoogle Scholar
  • 108 Krenkel O, Hundertmark J, Abdallah AT. et al. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. Gut 2020; 69 (03) 551-563
    CrossrefPubMedGoogle Scholar
  • 109 Park SR, Cho CS, Xi J, Kang HM, Lee JH. Holistic characterization of single-hepatocyte transcriptome responses to high-fat diet. Am J Physiol Endocrinol Metab 2021; 320 (02) E244-E258
    CrossrefPubMedGoogle Scholar
  • 110 Su Q, Kim SY, Adewale F. et al. Single-cell RNA transcriptome landscape of hepatocytes and non-parenchymal cells in healthy and NAFLD mouse liver. iScience 2021; 24 (11) 103233
    CrossrefPubMedGoogle Scholar
  • 111 Zhang H, Ma Y, Cheng X. et al. Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med 2021; 13 (614) eabd1206
    CrossrefPubMedGoogle Scholar
  • 112 Zheng C, Zheng L, Yoo JK. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017; 169 (07) 1342-1356.e16
    CrossrefPubMedGoogle Scholar
  • 113 Ma L, Hernandez MO, Zhao Y. et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 2019; 36 (04) 418-430.e6
    CrossrefPubMedGoogle Scholar
  • 114 Tamburini BAJ, Finlon JM, Gillen AE. et al. Chronic liver disease in humans causes expansion and differentiation of liver lymphatic endothelial cells. Front Immunol 2019; 10: 1036
    CrossrefPubMedGoogle Scholar
  • 115 Ramachandran P, Dobie R, Wilson-Kanamori JR. et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 2019; 575 (7783) 512-518
    CrossrefPubMedGoogle Scholar
  • 116 Zhang Q, He Y, Luo N. et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 2019; 179 (04) 829-845.e20
    CrossrefPubMedGoogle Scholar
  • 117 Sharma A, Seow JJW, Dutertre CA. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 2020; 183 (02) 377-394.e21
    CrossrefPubMedGoogle Scholar